Three-statement Excel model · 23 quarters and 5 fiscal years of history · 9 quarters and 5 fiscal years of projections
About the LLY model
This three-statement Excel model covers Eli Lilly and Company (LLY): its income statement, balance sheet and cash flow statement. It holds 23 quarters and 5 fiscal years of history and 9 quarters and 5 fiscal years of projections.
Projected revenue is built from KPI drivers: Eleven filed products across five therapeutic areas, each grown off the same quarter a year earlier; area subtotals and revenue are sums, across 11 segments.
Beyond the income statement, the workbook has these sections: KPI Drivers, Balance Sheet and Cash Flow Statement.
Model thesis: Converges on the Street after the guided H2 step-down never came: FY26E revenue $91.5B at the raised guide midpoint, and GAAP EPS still carries the acquired IPR&D the guide excludes, now $8.0B in FY27E
On November 12, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated November 12, 2026.
Income statement preview
Columns 2023–2025 are actual results and FY26E–FY28E are our estimates. Figures were recalculated in Excel on November 12, 2026. Dollars in millions, except per share.
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| 2023 | 2024 | 2025 | FY26E | FY27E | FY28E | |
| Mounjaro | $5,163.1 | $11,540.1 | $22,966.0 | $40,280.3 | $48,175.5 | $53,956.5 |
| Zepbound | 175.8 | 4,925.7 | 13,542.0 | 19,638.1 | 22,950.0 | 25,933.5 |
| Trulicity | 7,132.5 | 5,253.5 | 4,276.0 | 3,922.2 | 3,333.9 | 2,833.8 |
| Jardiance | 2,744.7 | 3,340.9 | 3,432.0 | 5,063.8 | 4,898.0 | 5,044.9 |
| Other Cardiometabolic Health | 4,451.6 | 4,460.7 | 4,006.0 | 4,512.6 | 7,220.2 | 9,747.3 |
| Cardiometabolic Health | $19,667.7 | $29,520.9 | $48,222.0 | $73,417.0 | $86,577.6 | $97,516.0 |
| Verzenio | $3,863.3 | $5,306.6 | $5,723.0 | $5,805.7 | $5,631.5 | $5,349.9 |
| Other Oncology | 2,795.0 | 3,445.8 | 3,653.0 | 4,311.0 | 5,087.0 | 5,850.0 |
| Oncology | $6,658.3 | $8,752.4 | $9,376.0 | $10,116.7 | $10,718.5 | $11,199.9 |
| Taltz | $2,759.6 | $3,260.4 | $3,563.0 | $3,314.0 | $3,048.9 | $2,805.0 |
| Other Immunology | 1,037.8 | 1,132.5 | 1,684.0 | 2,235.9 | 2,906.7 | 3,546.2 |
| Immunology | $3,797.4 | $4,392.9 | $5,247.0 | $5,549.9 | $5,955.6 | $6,351.2 |
| Neuroscience | $2,878.5 | $1,473.4 | $1,391.0 | $1,728.8 | $2,161.0 | $2,593.2 |
| Other | 1,122.2 | 903.0 | 943.0 | 696.1 | 696.1 | 696.1 |
| Disaggregation Rounding | 0.0 | 0.1 | 0.0 | 1.0 | 0.0 | 0.0 |
| Revenue | $34,124.1 | $45,042.7 | $65,179.0 | $91,509.5 | $106,108.7 | $118,356.4 |
| Less: Cost of Sales | ($7,082.2) | ($8,418.3) | ($11,052.0) | ($14,769.7) | ($16,532.7) | ($17,952.9) |
| Gross Profit | $27,041.9 | $36,624.4 | $54,127.0 | $76,739.8 | $89,576.1 | $100,403.6 |
| Less: Research and Development | ($9,313.4) | ($10,990.6) | ($13,337.0) | ($16,054.5) | ($18,553.3) | ($20,412.7) |
| Less: Marketing, Selling and Administrative | (7,403.1) | (8,593.8) | (11,094.0) | (13,286.0) | (14,622.7) | (15,822.5) |
| Less: Acquired In-Process Research and Development | (3,799.8) | (3,280.4) | (2,910.0) | (8,758.0) | (7,958.2) | (7,693.2) |
| Less: Asset Impairment, Restructuring and Other Special Charges | (67.7) | (860.6) | (484.0) | (1,528.4) | (1,061.1) | (1,183.6) |
| Total Operating Expenses | ($20,584.0) | ($23,725.4) | ($27,825.0) | ($39,626.8) | ($42,195.2) | ($45,111.9) |
| Operating Income | $6,457.9 | $12,899.0 | $26,302.0 | $37,113.0 | $47,380.8 | $55,291.7 |
| Less: Other-Net, (Income) Expense | $96.7 | ($218.6) | ($571.0) | ($241.4) | ($955.0) | ($946.9) |
| Income Before Income Taxes | $6,554.6 | $12,680.4 | $25,731.0 | $36,871.6 | $46,425.8 | $54,344.8 |
| Less: Income Taxes | ($1,314.2) | ($2,090.4) | ($5,091.0) | ($7,323.7) | ($9,248.6) | ($10,542.9) |
| Net Income | $5,240.4 | $10,590.0 | $20,640.0 | $29,548.0 | $37,177.3 | $43,801.9 |
| Ratios & Assumptions | ||||||
| Gross Margin | 79.2% | 81.3% | 83.0% | 83.9% | 84.4% | 84.8% |
| Incremental Gross Margin | 91.9% | 87.8% | 86.9% | 85.9% | 87.9% | 88.4% |
| Operating Margin | 18.9% | 28.6% | 40.4% | 40.6% | 44.7% | 46.7% |
| Net Margin | 15.4% | 23.5% | 31.7% | 32.3% | 35.0% | 37.0% |
| Effective Tax Rate | 20.1% | 16.5% | 19.8% | 19.9% | 19.9% | 19.4% |
The full workbook adds 23 historical and 9 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement — every subtotal a live formula, every projection traced to a driver.
Eli Lilly and Company research
Aardvark Labs Capital Research has published 6 reports on Eli Lilly and Company (LLY). The latest is the Q3 2026 Earnings Recap, published October 30, 2026, rated Hold.
The Step-Down Never Came and Lilly Lifts Its Revenue Guide $5.5B, But a 10% Two-Day Run Prices It In. Downgrading to Hold
Methodology
Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.